The global antibodies contract manufacturing market is expected to reach from USD 13.4 billion in 2022 to USD 35.9 billion by 2030, registering a CAGR of 13.1% from 2022 to 2030.

Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells.

Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics.

Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market.

For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes.

Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 70.9% in 2021, owing to the high penetration of mammalian expression systems for biologics development.

Based on the source offered in this market, the mammalian segment contributed the largest share of 58.5% in 2021, as they are considered a more reliable, robust, and relatively mature technology.

Asia Pacific is expected to emerge as the fastest-growing regional market with a CAGR of 13.3% from 2022 to 2030, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition.

Antibodies Contract Manufacturing Market Size and Market Analysis

Source : https://www.researchandmarkets.com/reports/5595846/antibodies-contract-manufacturing-market-size

The global Artificial Intelligence in Drug Discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period.

The growth of this Artificial Intelligence in Drug Discovery Market is driven by the growing need to control drug discovery & development costs, and growing number of cross-industry collaborations and partnerships, On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

Services segment is expected to grow at the highest rate during the forecast period.

Based on offering, the AI in drug discovery market is segmented into software and services. In 2021, the services segment accounted for the largest market share of the global AI in drug discovery services market and also expected to grow at the highest CAGR during the forecast period. The benefits associated with AI services and the strong demand for AI services among end users are the key factors driving the growth of this market segment.

Machine learning technology segment accounted for the largest share of the global AI in drug discovery market.

Based on technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. The machine learning technology segment further segmented into deep learning, supervised learning. reinforcement learning, unsupervised learning, and other machine learning technologies. Deep learning segment accounted for the largest share of the market in 2021, and this segment also expected to grow at the highest CAGR during the forecast period.

The immuno-oncology application segment accounted for the largest share of the AI in drug discovery market in 2021.

On the basis of application, the AI in drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular diseases, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of the market in 2021, owing to the increasing demand for effective cancer drugs. The neurodegenerative diseases segment is estimated to register the highest CAGR during the forecast period. The role of AI in resolving existing complexities in neurological drug development and strategic collaborations between pharmaceutical companies & solution providers are the key factors responsible for the high growth rate of the neurodegenerative diseases segment.

Pharmaceutical & biotechnology companies segment accounted for the largest share of the global AI in drug discovery market.

On the basis of end user, the AI in drug discovery market is segmented into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. The pharmaceutical & biotechnology companies segment accounted for the largest market share of AI in drug discovery market, in 2021, while the research centers and academic & government institutes segment is projected to register the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is driving the growth of this end-user segment.

North America is expected to dominate the Artificial Intelligence in Drug Discovery Market in 2022.

North America accounted for the largest share of the global AI in drug discovery market in 2021 and also expected to grow at the highest CAGR during the forecast period. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the key factors responsible for the large share and high growth rate of this market

Prominent players in this Artificial Intelligence in Drug Discovery Market are NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrödinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), BERG LLC (US), Cloud Pharmaceuticals (US), Insilico Medicine (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), Owkin, Inc. (US), XtalPi (US), Verge Genomics (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Source : https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html

Systemic Lupus Erythematosus Market to Advance Upto Whopping USD 10 Billion by 2030.

Systemic Lupus Erythematosus market size increment is a direct consequence of expected entry of promising emerging therapies, increasing awareness of the disease, and recent advancements in research and development in the 7MM.

• The Systemic Lupus Erythematosus market size in the 7MM was valued at USD 1,462 Million in 2020 and is expected to increase drastically owing to the launches of several potential emerging therapies during the study period (2018-2030).
• Key pharmaceutical Systemic Lupus Erythematosus companies such as GlaxoSmithKline, AstraZeneca, Sanofi, Eli Lilly and Company/Nektar Therapeutics, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Alpine Immune Sciences, Johnson & Johnson (Janssen), Idorsia Pharmaceuticals, Resolve Therapeutics, Amgen, AbbVie, Novartis, Corestem, Horizon Therapeutics, Boston Pharmaceuticals, InnoCare Pharma, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma/MorphoSys AG, Chipscreen Biosciences, and others are reported to bring a significant shift in the Systemic Lupus Erythematosus.
• The Systemic Lupus Erythematosus emerging therapies that are expected to launch in the forecast period include Dapirolizumab pegol, BIIB059, Obinutuzumab (Gazyva/Gazyvaro), IPP-201101 (Lupuzor),  and others.
• The United States accounted for the largest Systemic Lupus Erythematosus market size that was valued at USD 1,181 million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• The current Systemic Lupus Erythematosus therapeutic landscape in the 7MM is driven by current treatment practices and the expected launch of emerging therapies.

Systemic Lupus Erythematosus Overview

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. The pathogenesis of Systemic Lupus Erythematosus is complex, and the understanding of SLE pathogenesis is constantly evolving. A break in the tolerance in genetically susceptible individuals, on exposure to environmental factors, leads to the activation of autoimmunity.

There is no complete cure for Systemic Lupus Erythematosus currently, but there are many treatments available to help particular symptoms. Systemic Lupus Erythematosus involves a wide range of clinical features that encompasses vascular, immune, and fibrotic manifestations along with the involvement of many organs. Systemic Lupus Erythematosus treatment includes NSAIDs and antimalarial agents, which are the first-line therapies for mild Systemic Lupus Erythematosus. In addition, glucocorticoids and cytotoxic or immunosuppressive agents—such as azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, and methotrexate —are used for Systemic Lupus Erythematosus treatment with organ involvement. The current Systemic Lupus Erythematosus market possesses two approved products, Benlysta (belimumab) and Saphnelo (anifrolumab-fnia). 

Systemic Lupus Erythematosus Market Size & Market Analysis

The dynamics of the Systemic Lupus Erythematosus market is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. It includes several  Systemic Lupus Erythematosus pipeline therapies such as Lupuzor (also known as IPP-201101), being developed by ImmuPharma, is a 21-mer linear peptide fragment analog. ImmuPharma has completed the Phase III clinical trial for the treatment of SLE. Lupuzor demonstrated a superior response rate over placebo (61.5% vs 47.3%). ImmuPharma and Avion Pharmaceuticals signed exclusive license and development agreement for Lupuzor to fund a new ‘optimized’ international Phase III trial which is expected to start by 2022. Avion Pharmaceuticals has the exclusive rights for the commercialization of Lupuzor in the US. ImmuPharma retains all the rights to commercialize Lupuzor outside the US. Apart from this, Biogen is developing, BIIB059, is an investigational humanized monoclonal antibody that specifically recognizes and binds to blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. Biogen is conducting  Phase III clinical trials for the treatment of patients receiving Active SLE receiving background nonbiologic lupus standard of care. 

In addition, Dapirolizumab pegol is being developed by UCB Pharma in partnership with Biogen. It is an investigational humanized anti-CD40L antibody fragment that acts by preventing the interaction between CD40L on T-cells with CD40 on antigen-presenting cells through interactions with its receptor-CD40. The drug failed to meet its primary endpoint in the Phase II trial. However, the company continued the development of dapirolizumab pegol. The product is currently being developed jointly by UCB and Biogen to treat SLE in a Phase III trial. The topline results are expected in the first-half of 2024.

Systemic Lupus Erythematosus Epidemiology Segmentation

The total diagnosed prevalent Systemic Lupus Erythematosus population in the 7MM was found to be  651,965 in 2020 which is expected to increase during the study period.

The United States accounted for 351,176 Systemic Lupus Erythematosus prevalent cases.

Systemic Lupus Erythematosus Pipeline Therapies and Key Companies

• Itolizumab: Equillium/Biocon Limited
• ICP-022: InnoCare Pharma
• BOS161721: Boston Pharmaceuticals
• NKTR-358: Nektar Therapeutics/Eli Lilly
• ABBV-599: AbbVie
• Deucravacitinib: Bristol Myers Squibb
• BIIB059: Biogen
• Gazyva/Gazyvaro (Obinutuzumab): Hoffman-La-Roche
• Lupuzor: ImmuPharma
• SAR441344: Sanofi

Systemic Lupus Erythematosus Market Dynamics

The expected launch of potential SLE therapies is the main factor responsible for an increase in the Systemic Lupus Erythematosus market size in the coming years, assisted by an increase in the diagnosed Systemic Lupus Erythematosus prevalent population. Also, owing to the positive outcomes of the several products during the developmental stage by many key players, and improvement in the research and development activities for efficient treatment options to be made available in the market will directly boost the Systemic Lupus Erythematosus market. The increased awareness of the disease is also considered an aspect driving the Systemic Lupus Erythematosus market growth.

On the other hand, factors such as a high annual cost and the hit and trial approach of researchers serve as setbacks for the Systemic Lupus Erythematosus market growth. The high failure rate of emerging drugs makes entering the SLE market challenging for the pharmaceutical key players. Also, several obstacles experienced in the Systemic Lupus Erythematosus pipeline, undiagnosed and unreported cases might also play as obstructions in the Systemic Lupus Erythematosus market in the future.

Systemic Lupus Erythematosus Market Size & Market Analysis

Source : https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market-insight